Literature DB >> 1355785

Melioidosis and safety in the clinical laboratory.

L R Ashdown1.   

Abstract

Human infection with Pseudomonas pseudomallei, the causative agent of melioidosis, typically produces subclinical disease and an asymptomatic carrier state; occasionally clinical illness, frequently with a fatal outcome, may occur. Consequently, to help protect staff from laboratory-acquired melioidosis, microbiological and biomedical laboratories must have adequate facilities for safe work procedures and laboratory staff must engage in safe work practices. Recommendations from a melioidosis-endemic, diagnostic laboratory for the prevention of laboratory-acquired infection with this bacterium are essentially Category 3 (Advisory Committee on Dangerous Pathogens), Risk Group 3 (Australian Standards) or Biosafety Level 2 (National Institutes of Health) precautions. These include safeguards for centrifugation, prohibiting the 'sniff' test and the use of a biological safety cabinet for sputum processing, for subculture of stock strains, for preparation of antigen and for research studies but not for routine diagnostic techniques with P. pseudomallei.

Entities:  

Mesh:

Year:  1992        PMID: 1355785     DOI: 10.1016/0195-6701(92)90140-h

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei.

Authors:  Ryan T Novak; Mindy B Glass; Jay E Gee; Daniel Gal; Mark J Mayo; Bart J Currie; Patricia P Wilkins
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 2.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Comparison of rapid, automated ribotyping and DNA macrorestriction analysis of Burkholderia pseudomallei.

Authors:  Timothy J J Inglis; Lyn O'Reilly; Niki Foster; Adele Clair; Judy Sampson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

Review 4.  Laboratory-associated infections and biosafety.

Authors:  D L Sewell
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 5.  Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.

Authors:  Peera Hemarajata; Jonathan D Baghdadi; Risa Hoffman; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

6.  Burkholderia pseudomallei infection in a cystic fibrosis patient from the Caribbean: a case report.

Authors:  Dimas Mateos Corral; Allan L Coates; Yvonne C W Yau; Raymond Tellier; Mindy Glass; Steven M Jones; Valerie J Waters
Journal:  Can Respir J       Date:  2008 Jul-Aug       Impact factor: 2.409

7.  Notes from the Field: Travel-Associated Melioidosis and Resulting Laboratory Exposures - United States, 2016.

Authors:  Patrick K Mitchell; Colin Campbell; Martha P Montgomery; Julie Paoline; Christopher Wilbur; Leah Posivak-Khouly; Kristin Garafalo; Mindy Elrod; Lindy Liu; Andre Weltman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-22       Impact factor: 17.586

8.  Imported melioidosis, Israel, 2008.

Authors:  Avivit Cahn; Benjamin Koslowsky; Ran Nir-Paz; Violeta Temper; Nurit Hiller; Alla Karlinsky; Itzhak Gur; Carlos Hidalgo-Grass; Samuel N Heyman; Allon E Moses; Colin Block
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.